Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Erectile Dysfunction Treatment Drugs Market by Type (Phosphodiesterase Type 5 Inhibitors, Prostaglandin E1), By Application (Hospitals, Clinic, Others) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Erectile Dysfunction Treatment Drugs Market by Type (Phosphodiesterase Type 5 Inhibitors, Prostaglandin E1), By Application (Hospitals, Clinic, Others) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 241528 4200 Pharma & Healthcare 377 154 Pages 4.7 (31)
                                          

Market Overview:


The global erectile dysfunction treatment drugs market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of erectile dysfunction, rising awareness about available treatments, and growing demand for novel therapies. The phosphodiesterase type 5 inhibitors segment is expected to account for the largest share of the global erectile dysfunction treatment drugs market in 2018. This segment is anticipated to grow at a CAGR of 5.7% during the forecast period from 2018 to 2030 due to its high efficacy and safety profile.


Global Erectile Dysfunction Treatment Drugs Industry Outlook


Product Definition:


Erectile dysfunction drugs, also called phosphodiesterase type 5 inhibitors, are used to treat erectile dysfunction (ED), a condition in which a man cannot get or keep an erection. The most common drug in this class is sildenafil (Viagra). These drugs work by increasing blood flow to the penis.


Phosphodiesterase Type 5 Inhibitors:


Phosphodiesterase type 5 inhibitors, it's usage and growth factor in erectile dysfunction treatment drugs market: The global phosphodiesterase type 5 inhibitors, it's usage and growth factor in erectile dysfunction treatment drugs market size was valued at USD 2.8 billion in 2015. It is expected to witness a CAGR of XX% during the forecast period.


Prostaglandin E1:


Prostaglandin E1 is a prostacyclin and it's analog. It has been observed to be effective in the treatment of erectile dysfunction by enhancing penile blood flow. By inhibiting platelet aggregation, it helps in increasing the inflow of blood into the penis for sexual stimulation.


prostaglandins (PGs) are natural substances produced by certain body parts such as prostate gland, thymus,.


Application Insights:


Based on application, the global market is segmented into hospitals, clinics and other medical facilities. Hospitals were the largest revenue-generating centers due to factors such as a large patient base and prevalence of chronic diseases that require long term treatment. This factor has led to an increase in demand for erection drugs in this region.


The others segment includes companies offering online services as well as those operating outside of the healthcare sector (for instance, via direct sales). These companies are involved in various activities such as manufacturing/importation/exportation of erection drugs with niche applications or usage patterns. The growth rate of this segment can be attributed to increasing demand from non-healthcare professionals for effective treatment options without traveling frequently or staying overnight at a hospital bedside.


Regional Analysis:


North America dominated the global market in 2017 owing to a rise in the prevalence of erectile dysfunction among all age groups. Moreover, high demand for PDE5 inhibitors due to their efficiency and low cost is driving this regional market. The region is expected to maintain its dominance throughout the forecast period on account of increasing R&D investments by major companies and rising healthcare expenditure by governments.


Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising disposable income, improving healthcare infrastructure, growing patient awareness levels about available treatment options & availability of effective therapies for ED and other sexual disorders coupled with promotional activities by various organizations such as WHO & APICER that provide free samples & information regarding these drugs leading to an increase in prescriptions and consequently sales of PDE5 inhibitors especially Viagra (sildenafil citrate) which accounted for more than 80% share of this segment globally.


Growth Factors:


  • Increasing prevalence of erectile dysfunction
  • Growing awareness about available treatments for erectile dysfunction
  • Rising demand for effective and safe treatments for erectile dysfunction
  • Availability of generic versions of branded drugs
  • Growing investment in research and development

Scope Of The Report

Report Attributes

Report Details

Report Title

Erectile Dysfunction Treatment Drugs Market Research Report

By Type

Phosphodiesterase Type 5 Inhibitors, Prostaglandin E1

By Application

Hospitals, Clinic, Others

By Companies

Pfizer Inc., Dong-A Pharmaceutical Co. Ltd, Vivus, Inc., Meda Pharmaceuticals, Bayer AG, Johnson & Johnson Services, Apricus Biosciences, Eli Lilly

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

154

Number of Tables & Figures

108

Customization Available

Yes, the report can be customized as per your need.


Global Erectile Dysfunction Treatment Drugs Market Report Segments:

The global Erectile Dysfunction Treatment Drugs market is segmented on the basis of:

Types

Phosphodiesterase Type 5 Inhibitors, Prostaglandin E1

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Hospitals, Clinic, Others

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Pfizer Inc.
  2. Dong-A Pharmaceutical Co. Ltd
  3. Vivus, Inc.
  4. Meda Pharmaceuticals
  5. Bayer AG
  6. Johnson & Johnson Services
  7. Apricus Biosciences
  8. Eli Lilly

Global Erectile Dysfunction Treatment Drugs Market Overview


Highlights of The Erectile Dysfunction Treatment Drugs Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Phosphodiesterase Type 5 Inhibitors
    2. Prostaglandin E1
  1. By Application:

    1. Hospitals
    2. Clinic
    3. Others
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Erectile Dysfunction Treatment Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Erectile Dysfunction Treatment Drugs Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


There are many different types of drugs used to treat erectile dysfunction. Some of the most common treatments include phosphodiesterase type 5 inhibitors (such as sildenafil), penile injections (such as alprostadil), and vacuum devices.

Some of the key players operating in the erectile dysfunction treatment drugs market are Pfizer Inc., Dong-A Pharmaceutical Co. Ltd, Vivus, Inc., Meda Pharmaceuticals, Bayer AG, Johnson & Johnson Services, Apricus Biosciences, Eli Lilly.

The erectile dysfunction treatment drugs market is expected to register a CAGR of 5.5%.

                                            
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Erectile Dysfunction Treatment Drugs Market Overview    4.1 Introduction       4.1.1 Market Taxonomy       4.1.2 Market Definition       4.1.3 Macro-Economic Factors Impacting the Market Growth    4.2 Erectile Dysfunction Treatment Drugs Market Dynamics       4.2.1 Market Drivers       4.2.2 Market Restraints       4.2.3 Market Opportunity    4.3 Erectile Dysfunction Treatment Drugs Market - Supply Chain Analysis       4.3.1 List of Key Suppliers       4.3.2 List of Key Distributors       4.3.3 List of Key Consumers    4.4 Key Forces Shaping the Erectile Dysfunction Treatment Drugs Market       4.4.1 Bargaining Power of Suppliers       4.4.2 Bargaining Power of Buyers       4.4.3 Threat of Substitution       4.4.4 Threat of New Entrants       4.4.5 Competitive Rivalry    4.5 Global Erectile Dysfunction Treatment Drugs Market Size & Forecast, 2018-2028       4.5.1 Erectile Dysfunction Treatment Drugs Market Size and Y-o-Y Growth       4.5.2 Erectile Dysfunction Treatment Drugs Market Absolute $ Opportunity

Chapter 5 Global Erectile Dysfunction Treatment Drugs Market Analysis and Forecast by Type
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities by Type
      5.1.2 Basis Point Share (BPS) Analysis by Type
      5.1.3 Absolute $ Opportunity Assessment by Type
   5.2 Erectile Dysfunction Treatment Drugs Market Size Forecast by Type
      5.2.1 Phosphodiesterase Type 5 Inhibitors
      5.2.2 Prostaglandin E1
   5.3 Market Attractiveness Analysis by Type

Chapter 6 Global Erectile Dysfunction Treatment Drugs Market Analysis and Forecast by Applications
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities by Applications
      6.1.2 Basis Point Share (BPS) Analysis by Applications
      6.1.3 Absolute $ Opportunity Assessment by Applications
   6.2 Erectile Dysfunction Treatment Drugs Market Size Forecast by Applications
      6.2.1 Hospitals
      6.2.2 Clinic
      6.2.3 Others
   6.3 Market Attractiveness Analysis by Applications

Chapter 7 Global Erectile Dysfunction Treatment Drugs Market Analysis and Forecast by Region
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities by Region
      7.1.2 Basis Point Share (BPS) Analysis by Region
      7.1.3 Absolute $ Opportunity Assessment by Region
   7.2 Erectile Dysfunction Treatment Drugs Market Size Forecast by Region
      7.2.1 North America
      7.2.2 Europe
      7.2.3 Asia Pacific
      7.2.4 Latin America
      7.2.5 Middle East & Africa (MEA)
   7.3 Market Attractiveness Analysis by Region

Chapter 8 Coronavirus Disease (COVID-19) Impact 
   8.1 Introduction 
   8.2 Current & Future Impact Analysis 
   8.3 Economic Impact Analysis 
   8.4 Government Policies 
   8.5 Investment Scenario

Chapter 9 North America Erectile Dysfunction Treatment Drugs Analysis and Forecast
   9.1 Introduction
   9.2 North America Erectile Dysfunction Treatment Drugs Market Size Forecast by Country
      9.2.1 U.S.
      9.2.2 Canada
   9.3 Basis Point Share (BPS) Analysis by Country
   9.4 Absolute $ Opportunity Assessment by Country
   9.5 Market Attractiveness Analysis by Country
   9.6 North America Erectile Dysfunction Treatment Drugs Market Size Forecast by Type
      9.6.1 Phosphodiesterase Type 5 Inhibitors
      9.6.2 Prostaglandin E1
   9.7 Basis Point Share (BPS) Analysis by Type 
   9.8 Absolute $ Opportunity Assessment by Type 
   9.9 Market Attractiveness Analysis by Type
   9.10 North America Erectile Dysfunction Treatment Drugs Market Size Forecast by Applications
      9.10.1 Hospitals
      9.10.2 Clinic
      9.10.3 Others
   9.11 Basis Point Share (BPS) Analysis by Applications 
   9.12 Absolute $ Opportunity Assessment by Applications 
   9.13 Market Attractiveness Analysis by Applications

Chapter 10 Europe Erectile Dysfunction Treatment Drugs Analysis and Forecast
   10.1 Introduction
   10.2 Europe Erectile Dysfunction Treatment Drugs Market Size Forecast by Country
      10.2.1 Germany
      10.2.2 France
      10.2.3 Italy
      10.2.4 U.K.
      10.2.5 Spain
      10.2.6 Russia
      10.2.7 Rest of Europe
   10.3 Basis Point Share (BPS) Analysis by Country
   10.4 Absolute $ Opportunity Assessment by Country
   10.5 Market Attractiveness Analysis by Country
   10.6 Europe Erectile Dysfunction Treatment Drugs Market Size Forecast by Type
      10.6.1 Phosphodiesterase Type 5 Inhibitors
      10.6.2 Prostaglandin E1
   10.7 Basis Point Share (BPS) Analysis by Type 
   10.8 Absolute $ Opportunity Assessment by Type 
   10.9 Market Attractiveness Analysis by Type
   10.10 Europe Erectile Dysfunction Treatment Drugs Market Size Forecast by Applications
      10.10.1 Hospitals
      10.10.2 Clinic
      10.10.3 Others
   10.11 Basis Point Share (BPS) Analysis by Applications 
   10.12 Absolute $ Opportunity Assessment by Applications 
   10.13 Market Attractiveness Analysis by Applications

Chapter 11 Asia Pacific Erectile Dysfunction Treatment Drugs Analysis and Forecast
   11.1 Introduction
   11.2 Asia Pacific Erectile Dysfunction Treatment Drugs Market Size Forecast by Country
      11.2.1 China
      11.2.2 Japan
      11.2.3 South Korea
      11.2.4 India
      11.2.5 Australia
      11.2.6 South East Asia (SEA)
      11.2.7 Rest of Asia Pacific (APAC)
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 Asia Pacific Erectile Dysfunction Treatment Drugs Market Size Forecast by Type
      11.6.1 Phosphodiesterase Type 5 Inhibitors
      11.6.2 Prostaglandin E1
   11.7 Basis Point Share (BPS) Analysis by Type 
   11.8 Absolute $ Opportunity Assessment by Type 
   11.9 Market Attractiveness Analysis by Type
   11.10 Asia Pacific Erectile Dysfunction Treatment Drugs Market Size Forecast by Applications
      11.10.1 Hospitals
      11.10.2 Clinic
      11.10.3 Others
   11.11 Basis Point Share (BPS) Analysis by Applications 
   11.12 Absolute $ Opportunity Assessment by Applications 
   11.13 Market Attractiveness Analysis by Applications

Chapter 12 Latin America Erectile Dysfunction Treatment Drugs Analysis and Forecast
   12.1 Introduction
   12.2 Latin America Erectile Dysfunction Treatment Drugs Market Size Forecast by Country
      12.2.1 Brazil
      12.2.2 Mexico
      12.2.3 Rest of Latin America (LATAM)
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Latin America Erectile Dysfunction Treatment Drugs Market Size Forecast by Type
      12.6.1 Phosphodiesterase Type 5 Inhibitors
      12.6.2 Prostaglandin E1
   12.7 Basis Point Share (BPS) Analysis by Type 
   12.8 Absolute $ Opportunity Assessment by Type 
   12.9 Market Attractiveness Analysis by Type
   12.10 Latin America Erectile Dysfunction Treatment Drugs Market Size Forecast by Applications
      12.10.1 Hospitals
      12.10.2 Clinic
      12.10.3 Others
   12.11 Basis Point Share (BPS) Analysis by Applications 
   12.12 Absolute $ Opportunity Assessment by Applications 
   12.13 Market Attractiveness Analysis by Applications

Chapter 13 Middle East & Africa (MEA) Erectile Dysfunction Treatment Drugs Analysis and Forecast
   13.1 Introduction
   13.2 Middle East & Africa (MEA) Erectile Dysfunction Treatment Drugs Market Size Forecast by Country
      13.2.1 Saudi Arabia
      13.2.2 South Africa
      13.2.3 UAE
      13.2.4 Rest of Middle East & Africa (MEA)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Middle East & Africa (MEA) Erectile Dysfunction Treatment Drugs Market Size Forecast by Type
      13.6.1 Phosphodiesterase Type 5 Inhibitors
      13.6.2 Prostaglandin E1
   13.7 Basis Point Share (BPS) Analysis by Type 
   13.8 Absolute $ Opportunity Assessment by Type 
   13.9 Market Attractiveness Analysis by Type
   13.10 Middle East & Africa (MEA) Erectile Dysfunction Treatment Drugs Market Size Forecast by Applications
      13.10.1 Hospitals
      13.10.2 Clinic
      13.10.3 Others
   13.11 Basis Point Share (BPS) Analysis by Applications 
   13.12 Absolute $ Opportunity Assessment by Applications 
   13.13 Market Attractiveness Analysis by Applications

Chapter 14 Competition Landscape 
   14.1 Erectile Dysfunction Treatment Drugs Market: Competitive Dashboard
   14.2 Global Erectile Dysfunction Treatment Drugs Market: Market Share Analysis, 2019
   14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.3.1 Pfizer Inc.
      14.3.2 Dong-A Pharmaceutical Co. Ltd
      14.3.3 Vivus, Inc.
      14.3.4 Meda Pharmaceuticals
      14.3.5 Bayer AG
      14.3.6 Johnson & Johnson Services
      14.3.7 Apricus Biosciences
      14.3.8 Eli Lilly

Our Trusted Clients

Contact Us